Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Lancet, Infect. dis.; 21 (6), 2021
Background A vaccine against COVID-19 is urgently needed for older adults, in whom morbidity and mortality due to the disease are increased. We aimed to assess the safety, tolerability, and immunogenicity of a candidate COVID-19 vaccine, CoronaVac, containing inactivated SARS-CoV-2, in adults aged 60 yea...
Anticorpos Neutralizantes, Anticorpos Antivirais, Formação de Anticorpos, COVID-19/prevenção & controle, Vacinas contra COVID-19/efeitos da radiação, Vacinas contra COVID-19/imunologia, Método Duplo-Cego, Imunogenicidade da Vacina, SARS-CoV-2, Vacinas de Produtos Inativados/imunologia, Moçambique/epidemiologia